These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 38027027)

  • 21. Role of Ferroptosis in Non-Alcoholic Fatty Liver Disease and Its Implications for Therapeutic Strategies.
    Zhang H; Zhang E; Hu H
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ferroptosis as an emerging therapeutic target in liver diseases.
    Lu Y; Hu J; Chen L; Li S; Yuan M; Tian X; Cao P; Qiu Z
    Front Pharmacol; 2023; 14():1196287. PubMed ID: 37256232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ferroptosis as a new therapeutic opportunity for nonviral liver disease.
    Jia M; Zhang H; Qin Q; Hou Y; Zhang X; Chen D; Zhang H; Chen Y
    Eur J Pharmacol; 2021 Oct; 908():174319. PubMed ID: 34252441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigallocatechin gallate alleviates high-fat diet-induced hepatic lipotoxicity by targeting mitochondrial ROS-mediated ferroptosis.
    Ding SB; Chu XL; Jin YX; Jiang JJ; Zhao X; Yu M
    Front Pharmacol; 2023; 14():1148814. PubMed ID: 37025486
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
    Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
    Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BDE-47 induces metabolic dysfunction-associated steatotic liver disease (MASLD) through CD36-mediated increased fatty acid uptake and PPARα-induced abnormal fatty acid oxidation in BALB/c mice.
    Xia B; Yu R; Liu J; Liu D; Li S; Yang L; Liu N; Liang B; Zeng J; Wei J; Lin G
    Toxicol Lett; 2024 Jan; 391():100-110. PubMed ID: 38040069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Discussion from metabolism to fatty liver disease: rethinking the origin of disease and the endpoint of new drugs or metabolic dysfunction-associated steatotic liver disease].
    Xue F; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):785-788. PubMed ID: 37723057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study.
    Sano T; Amano K; Ide T; Isoda H; Honma Y; Morita Y; Yano Y; Nakamura H; Itano S; Miyajima I; Shirachi M; Kuwahara R; Ohno M; Kawaguchi T; Tsutsumi T; Nakano D; Arinaga-Hino T; Kawaguchi M; Eguchi Y; Torimura T; Takahashi H; Harada M; Kawaguchi T;
    Hepatol Res; 2024 Apr; 54(4):326-335. PubMed ID: 37975277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease.
    Sawada K; Chung H; Softic S; Moreno-Fernandez ME; Divanovic S
    Cell Metab; 2023 Nov; 35(11):1852-1871. PubMed ID: 37939656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting ferroptosis, a novel programmed cell death, for the potential of alcohol-related liver disease therapy.
    Shi JF; Liu Y; Wang Y; Gao R; Wang Y; Liu J
    Front Pharmacol; 2023; 14():1194343. PubMed ID: 37214434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population.
    Dalbeni A; Garbin M; Zoncapè M; Romeo S; Cattazzo F; Mantovani A; Cespiati A; Fracanzani AL; Tsochatzis E; Sacerdoti D; Mantovani A; Lombardi R
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ferroptosis in Chronic Liver Diseases: Opportunities and Challenges.
    Zhou X; Fu Y; Liu W; Mu Y; Zhang H; Chen J; Liu P
    Front Mol Biosci; 2022; 9():928321. PubMed ID: 35720113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
    Hachuła M; Kosowski M; Basiak M; Okopień B
    Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37764998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ferroptotic Cell Death: New Regulatory Mechanisms for Metabolic Diseases.
    Le Y; Zhang Z; Wang C; Lu D
    Endocr Metab Immune Disord Drug Targets; 2021; 21(5):785-800. PubMed ID: 32735532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease.
    Arvaniti P; Giannoulis G; Lygoura V; Gatselis NK; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K; Dalekos GN
    Ann Gastroenterol; 2023; 36(6):661-669. PubMed ID: 38023979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.